Turn Therapeutics (NASDAQ:TTRX) Director Arthur Golden Buys 20,532 Shares

November 25, 2025 by InsiderTrades.com

Key Points

Director Arthur Golden purchased 20,532 shares at an average price of $2.87 per share (totaling $58,926.84), bringing his ownership to 50,734 shares — a 67.98% increase.
Shares of TTRX were reported up 7.0%, opening at $3.50, with a one‑year range of $2.57 to $26.50.
Turn Therapeutics last reported quarterly EPS of ($0.07) and develops pharmaceutical/medical device technologies, including its patented PermaFusion platform.

Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden bought 20,532 shares of the business's stock in a transaction that occurred on Friday, November 21st. The stock was purchased at an average cost of $2.87 per share, for a total transaction of $58,926.84. Following the completion of the transaction, the director owned 50,734 shares in the company, valued at $145,606.58. This trade represents a 67.98% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Turn Therapeutics Stock Up 7.0%

Shares of TTRX opened at $3.50 on Tuesday. Turn Therapeutics Inc. has a one year low of $2.57 and a one year high of $26.50.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.07) earnings per share for the quarter.

About Turn Therapeutics

(Get Free Report)

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Turn Therapeutics?

Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Turn Therapeutics and related companies.

From Our Partners